Picture of Mereo BioPharma logo

MREO Mereo BioPharma Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Mereo BioPharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARS20-F20-F10-K10-K
Standards:
IFRS
IFRS
IFRS
USG
USG
Status:
fx
Final
fx
Final
fx
Final
FinalFinal
Net Income/Starting Line-21319.6-44.5
Depreciation
Amortisation
Non-Cash Items166-29-4.628.879.7
Unusual Items
Other Non-Cash Items
Changes in Working Capital9.011.350.36-31.1-43.6
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-36.3-7.2-47.8-21.1-32.8
Capital Expenditures-0.021-0.736-0.012-0.419-0.699
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items1.940.1571.860
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Sale of Intangible Assets
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities1.92-0.5791.84-0.419-0.699
Financing Cash Flow Items-10.1-0.3220.188-0.444-0.853
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities44.5107-0.9667.9746.1
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash9.1397.4-46.8-10.812.4